Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human Adenosine Receptor A2a ELISA Kit (AC3045)
Cat.#: ASET-1634
Specifications
Description Human Adenosine Receptor A2a ELISA Kit allows for the in vitro quantitative determination of human Adenosine Receptor A2a concentrations in serum, plasma, tissue homogenates, and other biological fluids. The kit employs the sandwich enzyme immunoassay technique. Size 96T Sample Type Serum, plasma, tissue homogenates, and other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.281 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 0.469-30 ng/mL Assay Time 4h 30m Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1094 Human NEUROD4 ELISA Kit (AC2505) Quantitative inquiry ASET-1274 Human NDNF ELISA Kit (AC2685) Quantitative inquiry ASET-1916 Human Lgi4 ELISA Kit (AC3327) Quantitative inquiry ASET-1977 Human SynGAP ELISA Kit (AC3388) Quantitative inquiry ASET-2232 Rat GCLM ELISA Kit (AC3643) Quantitative inquiry ASET-1721 Rat Mitofusin 1 ELISA Kit (AC3132) Quantitative inquiry ASET-1492 Human GABARAPL1 ELISA Kit (AC2903) Quantitative inquiry ASET-2214 Rat FGF1 ELISA Kit (AC3625) Quantitative inquiry ASET-1216 Mouse VEGFC ELISA Kit (AC2627) Quantitative inquiry ASET-1756 Rat HEXA ELISA Kit (AC3167) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket